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Introduction
Almost 40 years ago, Chinese scientists
rediscovered the near-miraculous potency
of artemisinin derivatives against malaria.
Today, we are approaching a decade since
the World Health Organization (WHO)
recommended that artemisinin-based
combination therapies (ACTs) replace
older antimalarials rendered ineffective
by resistance [1]. Yet the global malaria
community—researchers, governments,
international organizations, funding agen-
cies, nongovernmental organizations, and
activists—has collectively failed to provide
widespread access to this treatment and to
minimize the threat of resistance. The
evidence is sobering:
N Although nearly all endemic countries
have adopted ACTs as first-line ther-
apy for Plasmodium falciparum malaria,
access on the ground remains danger-
ously low. In recent household surveys
from 18 African countries, on average
only 3% of febrile children under five
years received an ACT, while only
38% had access to other antimalarials.
African children comprise 85% of
global malaria deaths [2].
N T h ep a r a s i t ei sd e m o n s t r a t i n gd e -
creased sensitivity to artemisinin in
Cambodia, where use of artesunate
monotherapy and substandard artemi-
sinin-based drugs remains common
[3–5]. If artemisinin-resistant strains
of P. falciparum emerge and spread,
they would weaken the last effective
antimalarial we have.
Therefore, the Affordable Medicines
Facility–malaria or AMFm (see Box 1) is
a welcome step toward improving access
to this lifesaving treatment. Funding com-
mitments from UNITAID and the UK
Department for International Develop-
ment, along with the Global Fund to
Fight AIDS, Tuberculosis and Malaria
(GFATM) decision to host the facility,
have launched an ambitious global subsidy
on ACTs into operation. By lowering the
price of ACTs, the AMFm may broaden
access in the public sector. However, since
many governments already receive
GFATM support to purchase ACTs for
public use, the AMFm’s most dramatic
impact is likely to be on prices in the
private sector. (The term ‘‘private sector’’
here refers to for-profit entities and can
denote a wide range of drug outlets, from
small rural kiosks to regulated urban
pharmacies and private clinics.) Approxi-
mately half of suspected malaria patients
seek care outside the public sector in the
WHO African and Western Pacific re-
The Policy Forum allows health policy makers
around the world to discuss challenges and
opportunities for improving health care in their
societies.
Citation: Moon S, Pe ´rez Casas C, Kindermans J-M, de Smet M, von Schoen-Angerer T (2009) Focusing on
Quality Patient Care in the New Global Subsidy for Malaria Medicines. PLoS Med 6(7): e1000106. doi:10.1371/
journal.pmed.1000106
Published July 21, 2009
Copyright:  2009 Moon et al. This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
Funding: The authors received no specific funding for this article.
Competing Interests: JMK was an unpaid member of the Committee on the Economics of Antimalarial Drugs
for the Institute of Medicine 2004 report ‘‘Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of
Resistance,’’ which first proposed a subsidy. JMK and TvSA have been consulted as stakeholders during the
preparation of the technical proposal of the AMFm, but none of the authors had any role in the design nor any
other official role.
Abbreviations: ACT, artemisinin-based combination therapy; AMFm, Affordable Medicines Facility–malaria;
CHW, community health worker; CQ, chloroquine; FDC, fixed-dose combination; GFATM, Global Fund to Fight
AIDS, Tuberculosis and Malaria; M&E, monitoring and evaluation; MSF, Me ´decins Sans Frontie `res; MVW, malaria
village worker; RDT, rapid diagnostic test; SP, sulfadoxine-pyrimethamine; WHO, World Health Organization;
WHO-PQ, WHO-prequalified.
* E-mail: tido.von.schoenangerer@geneva.msf.org
Provenance: Not commissioned, externally peer reviewed
Box 1. The Affordable Medicines Facility–malaria (AMFm)
The Affordable Medicines Facility–malaria (AMFm), a new global health initiative,
aims to address inadequate access to ACT for treating P. falciparum malaria by
subsidizing producer prices. First proposed in 2004 [33], the facility is expected to
begin operating in late 2009. Resistance to older antimalarial drugs such as CQ or
SP is now widespread, making ACTs the most effective treatment for P.
falciparum, the deadliest variant of malaria; however, ACTs cost 10 to 20 times as
much as CQ or SP. The AMFm aims to lower end-user prices to the level of older
antimalarials in order to save lives by making ACTs more affordable and to delay
resistance to artemisinin derivatives by driving artemisinin monotherapy and
substandard antimalarials out of the market. The AMFm is hosted by the GFATM,
and 11 countries have been invited to participate in the initial phase: Benin,
Cambodia, Ghana, Kenya, Madagascar, Niger, Nigeria, Rwanda, Senegal, Tanzania,
and Uganda.
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Asian region [2].
ACT prices have significantly decreased
in recent years, mainly due to competition
(see Figure 1); however, they are still
costlier than most antimalarials. ACT
production incorporates a relatively ex-
pensive extraction, purification, and deriv-
atization process, the cost of the compan-
ion drug (e.g., amodiaquine), and the cost
of co-formulation for fixed-dose combina-
tions (FDCs). Thus, a subsidy is warranted
to bring ACT prices down to the level of
other antimalarials, at least until semi-
synthetic artemisinin production is avail-
able at adequate volume and low cost,
which is not expected before 2012 [6].
The AMFm is both promising and
ambitious. However, as the first major
global initiative of its kind, its precise
impact and consequences are still un-
known. As the AMFm prepares for its first
phase of implementation, it is critical to
recognize areas that require further atten-
tion, where additional research is urgently
needed, and how countries can best take
advantage of the opportunities it may offer.
In the first section we propose policies to
improve patient care. We then briefly
suggest measures that could improve
AMFm implementation. Finally, we dis-
cuss the implications of our analysis for
calibrating support for the public and
private sectors.
I. Focusing on Quality Patient
Care
The AMFm should adopt policies that
will enhance quality patient care, includ-
ing exclusively funding FDCs, withholding
support for ineffective combinations, and
supporting wider adoption of rapid diag-
nostic tests (RDTs).
By reducing pill count and making it
impossible for the patient to take artemisi-
nin monotherapy, FDCs can facilitate
patient adherence and reduce the risk of
resistance. The advantages of FDCs have
been demonstrated in several disease areas,
including tuberculosis and HIV/AIDS [7–
9]. Furthermore, problems with inappro-
priate use of ACT co-blisters have been
documented, such as removal of artesunate
from co-blisters for sale as monotherapy
[3]. In the near future, there are likely to be
two or more WHO-prequalified (WHO-
PQ) FDCs for two key drug combinations
(artemether/lumefantrine and artesunate/
amodiaquine); in addition, a pediatric FDC
of artesunate/mefloquine is in the WHO-
PQ assessment process [10]. (The new
GFATM quality assurance policy, which
will apply to the AMFm, allows the
purchase of products still undergoing
WHO-PQ assessment under certain con-
Figure 1. Evolution of prices for ACT adult treatment. Sources of prices are as follows: Artemether/lumefantrine (Novartis): Publicly announced
prices by Novartis September 29, 2006 [34]; Novartis April 23, 2008 [35], and WHO May 16, 2007 [36]. Artemether/lumefantrine (generic): Prices
quoted to MSF (manufacturer: Ajanta) followed by prices announced by Clinton HIV/AIDS Initiative (manufacturers: Cipla, IPCA) July17, 2008 [37].
Artesunate/amodiaquine FDC (DNDi/sanofi-aventis): Prices paid by MSF Logistique to manufacturer (MSF internal data). See also sanofi-aventis/DNDi
announcement [38]. Artesunate/amodiaquine co-blister average WHO/UNICEF co-tenders: average price from five tenders [39]. Artemisinin (raw
material): [40]. The artemisinin raw material considered here as the quantity needed for production of one adult treatment course with artesunate/
amodiaquine is 613 mg and 839 mg with artemether/lumefantrine (in both cases with 5% lost during manufacturing).
doi:10.1371/journal.pmed.1000106.g001
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manufacturers provides a viable way for
the AMFm to subsidize exclusively FDCs
from the outset, while encouraging generic
competition through a transparent process.
If there are insufficient FDCs available,
temporary use of co-blisters could be
acceptable. By endorsing the exclusive use
of FDCs, the AMFm would send a clear
signal to manufacturers to invest in the
rapid development of such formulations,
including all necessary quality, safety, and
efficacy considerations. Unfortunately,
while the AMFm Guidelines for Applica-
tions allow FDCpurchase,they do not limit
or phase out co-blisters [11].
Furthermore, the AMFm should not
support the purchase of a particular
combination when there is already signif-
icant resistance to the partner drug.
Specifically, the combination of artesu-
nate/sulfadoxine-pyrimethamine (SP) may
not be suitable for use in countries where
SP resistance or the risk of its emergence is
relatively high. Current AMFm guidelines
are silent on this issue [11].
In addition, the AMFm should support
wider use of RDTs to improve the quality
of patient care and minimize unnecessary
ACT use [12]. Me ´decins Sans Frontie `res
(MSF) has used RDTs in its field projects
since 2002, and has found that a surpris-
ingly high proportion of suspected malaria
cases in sub-Saharan Africa were, in fact,
not malaria. For example, negative out-
comes comprised 35% of tested patients in
Bo District, Sierra Leone, where transmis-
sion is high year-round, and 40% in
Bongor District, Chad during the malaria
high season [13]. Accurate diagnosis offers
several benefits conducive to AMFm’s
broader objectives: if RDTs rule out
malaria, providers can seek and treat the
true cause of fever (or other symptoms),
ultimately preventing deaths from other
life-threatening illnesses [14,15]; patients’
perceptions of the efficacy of ACTs are
likely to improve if they only take ACTs
when they will be effective; and finally, the
risk of resistance to partner drugs (partic-
ularly those with a long half-life) is likely to
decrease with less ‘‘drug pressure’’ in the
population—that is, if only patients that
actually have malaria are taking ACTs.
The mere availability of RDTs is not
sufficient to guarantee improved out-
comes; for example, it is not unusual for
health care providers to prescribe an
antimalarial after a negative test result
[16–18], and quality may be compromised
due to poor manufacturing or prolonged
heat exposure [19,20]. Thus, careful
provider training and independent prod-
uct testing, as recently conducted by
WHO and its partners [21], are also
important to maximize the potential
benefits of RDTs.
While there is some experience using
RDTs in the public sector, including
through malaria village workers (MVWs)
[3,22,23], the feasibility and/or best strat-
egiesto promoteRDTs inthe privatesector
remain unclear. Challenges to implement-
ing RDT use in the private sector are
many, including incentives for private
vendors to overprescribe drugs or RDTs
to maximize sales, the necessity of setting
prices correctly to motivate their use, the
lack of trained staff to administer the RDT,
and concerns about the safety of taking
RDT blood samples outside a clinical
setting. The AMFm allows countries to
use expected savings from lower ACT costs
in current GFATM grants to expand RDT
use as a supporting intervention; countries
should take advantage of this opportunity.
Governments should also request funds for
operational research to improve RDT use
in the public sector and explore possibilities
for RDT provision in the private sector in
order to strengthen the evidence base for
the second phase of AMFm.
While decreasing ACT prices is a critical
step, achieving widespread access to effec-
tive malaria treatment will require an
approach to care that goes well beyond an
affordable drug. Among the supporting
interventions that AMFm requires are
‘‘interventions to expand ACT access to
poor people, especially the poorest quintile,
and other vulnerable groups’’ [11]. How
can such populations best be reached?
In a 2008 study in Mali, MSF found
that even when the public sector provided
ACTs free of charge, other fees (e.g., for
consultation or lab tests) could drive up
costs to make ACT treatment inaccessible
[22,24]. In Bo District, Sierra Leone, the
cost of health care per disease episode is 25
working days [24].
Furthermore, affordable health care
does little good when it is not geograph-
ically accessible. This issue is particularly
relevant for malaria, which can kill a child
within 24 hours after the onset of symp-
toms. In a 2008 study of malaria treatment
projects in Chad, Mali, and Sierra Leone,
MSF found that access to malaria treat-
ment improved dramatically only after the
implementation of decentralized delivery
models relying on trained MVWs to reach
rural areas, combined with decreasing or
abolishing user fees for health services
[24]. As an extension of the public health
system, the MVWs learned how to use
RDTs, provide ACTs for confirmed
malaria cases, and refer negative and
severe cases to health centers. Findings
from other contexts, including Cambodia
[3] and Eritrea [25], suggest that commu-
nity health workers (CHWs) can be an
effective means of reaching remote or
marginalized populations, particularly for
relatively straightforward interventions.
However, many questions remain re-
garding optimal management of CHWs or
MVWs, including how best to pay, retain,
train, supervise, and incorporate them into
the formal health system, how to maxi-
mize service uptake by the population, and
how to scale up to national level [26–29].
Nevertheless, the question of how to reach
patients in remote areas remains urgent:
the lack of geographical access to public
health centers was a primary rationale for
subsidizing ACTs in private outlets, in
hopes that they would better reach remote
areas; however, pilot projects indicate that
uptake of subsidized ACTs in remote rural
private sector outlets remained significant-
ly lower than in population centers [30].
Comparing the relative efficacy of MVWs
versus private sector subsidies in bringing
affordable ACTs to remote areas should
be a priority research question.
Indeed, operational research and mon-
itoring and evaluation efforts (M&E) will
be critical in AMFm’s Phase 1. AMFm is
encouraging countries to submit funding
requests for M&E and operational re-
search, and plans to carry out a multi-
country evaluation as well [11]. However,
up to this point, much of the policy debate
and research has focused either on the
AMFm’s potential impact on the emer-
gence of resistance, and/or its impact on
price. Of equal if not greater concern are
health outcomes. The application guide-
lines encourage countries to monitor ACT
availability, price, market share, and
barriers to access, but do not mention
health outcomes. Understanding the ex-
tent to which a subsidy meets patient
needs will require data on incidence of
uncomplicated malaria, severe malaria,
and mortality attributed to malaria, as
well as on ACT coverage, levels of
treatment literacy and adherence, and
ability to pay. As countries implement
various supporting interventions, it will be
critical to include patient-centered indica-
tors in monitoring efforts.
II. Securing Artemisinin Supply
and Removal of Artemisinin
Monotherapy
Several other measures could improve
the AMFm’s efficacy. First, the AMFm
should take steps to avoid repeating the
global artemisinin shortages in 2004–2005
that wreaked havoc on treatment pro-
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widely artemisinin raw materials prices
have fluctuated, and how lower raw
materials prices combined with generic
competition have reduced ACT prices.
Current estimates indicate a 40-ton short-
fall of the artemisinin starting material
needed to produce 240 million treatments
in 2010 [6]. The 2010 availability depends
on what is being planted by farmers today,
due to the 14-month time span required
from seed to finished product. Further-
more, the highly volatile food crop market
impacts artemisinin supply, and farmers’
decisions on whether to plant Artemisia
annua are subject to imperfect informa-
tion—thus, we cannot expect that market
forces alone will guarantee sufficient
supply in the short term. The malaria
community has moved too slowly to
stabilize the market. For example, in
January 2009 the UNITAID Board de-
layed approval of a revolving fund for this
purpose, meaning that the planting period
for Asian farmers was missed. The AMFm
should act as quickly as possible to ensure
a sufficient, stable artemisinin supply.
Second, countries should use regulatory
measures to implement the WHO ban on
artemisinin monotherapy and to remove
chloroquine (CQ) as a treatment option
for P. falciparum. Country experience shows
that subsidized ACTs only have a limited
effect in crowding less effective antimalar-
ials out of the market [3,30]. Not long
after WHO first called on manufacturers
to stop marketing artemisinin monothera-
py, 40 out of 74 identified manufacturers
announced their cooperation; today, 35 of
77 endemic countries either do not allow
the marketing of artemisinin monotherapy
or plan to disallow it soon [2,32]. A
combination of economic, regulatory,
and enforcement tools should be used to
remove artemisinin monotherapy and
ineffective antimalarials from the market.
III. Implications for Public and
Private Sector Support
A central issue raised hereand in debates
preceding the AMFm is how to calibrate
international support for the public and
private sectors. Patient use of each sector
differs substantially by country. For exam-
ple, in Cambodia 80%–90% of people seek
care for fever outside the public health
system,whileinSenegal75%dosothrough
the public sector [3,30,31].
Evidence from pilot projects implement-
ing private sector ACT subsidies reflects
wide variance between countries in each
sector’s capacity. For example, a pilot
subsidy in Tanzania translated into signif-
icantly lowered prices and increased use of
ACT through the private sector. In
contrast, in Cambodia, the publicly sup-
ported MVW program was far more
successful in increasing access to appro-
priate treatment compared to the private
sector–based social marketing of subsi-
dized RDTs and ACT co-blisters [30].
While pilots indicate that the AMFm can
improve access through the private sector,
the initiative should complement rather
than undermine public sector efforts,
particularly since some policies are far
easier to implement in the public sector,
including: using RDTs, providing free care
to the vulnerable, regulating trained health
staff, and avoiding perverse incentives to
overprescribe. It will be important to
monitor for any potential negative effects
the AMFm could have on public ACT
provision, particularly in countries with
high levels of public sector usage. Weak-
ening of public sector capacity could occur
for many reasons, including: decreased
international funding, competition with
the private sector for limited ACT stock
(of particular concern if raw material
shortages recur), declining political atten-
tion to improving public service provision,
and/or competing demands on limited
managerial and administrative resources
in national malaria control programs.
Currently, the guidelines put low priority
on expanding ACT availability in the
public sector; the AMFm should clarify
that countries may use the increased
affordability of ACTs to supply both the
private and public sectors.
IV. Conclusions
The AMFm is an innovative but
untested global initiative with the potential
for both positive and unintended conse-
quences for health. Keeping the focus on
quality care—through patient-centered
policies on drug choice, diagnostics, deliv-
ery, and M&E—will help the AMFm to
meet the long unfulfilled promise of
artemisinin for the millions who continue
to suffer from malaria today.
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